S. Korea's biopharmaceutical exports hit record US$6.6 bln in Jan.-Sept. period
SEOUL, Oct. 8 (Yonhap) -- South Korea's exports of biopharmaceutical products re...
South Korea's biopharmaceutical exports surged to a record US$6.6 billion in the first nine months of the year, driven by growing demand in Europe, according to government data released on Thursday. The Ministry of Food and Drug Safety reported a 15.8 percent increase in exports compared to the same period last year, bringing the total to an estimated $6.6 billion. The shipments constituted roughly 73 percent of the country's total pharmaceutical exports, valued at $9 billion during the period.
Biopharmaceutical exports experienced a 15.6 percent growth in the third quarter alone, reaching $2.07 billion. The United States emerged as the leading export destination, accounting for $1.07 billion or 16.3 percent of all shipments abroad. Switzerland followed with $1.01 billion, while Hungary ranked third with $920 million in sales.
Europe demonstrated particularly strong growth in biopharmaceutical exports, with seven of South Korea's top ten destinations located within the region. This surge was attributed to the robust demand for contract development and manufacturing organization (CDMO) services and biosimilar products.
Rewritten by urgent.news; may contain errors — check the original.
Sources: en.yna.co.kr · koreatimes.co.kr · aljazeera.com · theguardian.com
This story
This is one outlet's version. Read the fullest account.
- Korea says no confirmed fuel exports to Russia, vows strict enforcement of export controls koreatimes.co.kr
- South Korea threatens legal action if fuel shipments to Russia found to have broken law theguardian.com
- South Korea pledges legal action over alleged fuel exports to Russia aljazeera.com
- S. Korea says no confirmed fuel exports to Russia, vows strict enforcement of export controls en.yna.co.kr